ARVINAS, INC. ARVN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-09-27
ARVINAS, INC. statistics & valuation
Market cap$516.2M
P / S2.0×
P / B1.2×
Net margin-30.8%
Return on equity-18.6%
FCF margin-105.0%
Net cash$142.3M
Enterprise value USD$373.9M
Earnings yield EBIT/EV-31.7%
Return on capital-20.6%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -45.1% | -95.0% | -511.5% | -200.3% | -351.5% | -466.4% | -119.8% | -305.8% | -326.7% |
| Net margin | -30.8% | -75.5% | -467.9% | -215.0% | -356.3% | -460.6% | -163.5% | -289.6% | -317.3% |
| FCF margin | -105.0% | -99.1% | -446.8% | -213.3% | 1034.9% | -371.0% | -109.1% | -132.3% | 54.1% |
| Return on assets | -11.3% | -18.2% | -28.2% | -22.3% | -12.1% | -16.6% | -23.3% | -20.8% | -36.0% |
| Return on equity | -18.6% | -35.4% | -55.7% | -50.0% | -24.4% | -18.6% | -31.0% | -30.4% | 39.3% |
| Debt / equity | 0.00× | 0.00× | 0.00× | 0.00× | 0.00× | 0.00× | 0.01× | 0.02× | -0.00× |
| Current ratio | 4.92 | 4.64 | 4.98 | 4.20 | 5.93 | 14.29 | 8.86 | 8.52 | 3.67 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.